Carmen Cabellos

Publications (54) View all

• Article: Fosfomycin-Daptomycin and other Fosfomycin combinations as alternative therapies in experimental foreign body infection by methicillin resistant Staphylococcus aureus (MRSA).

  C Garrigós, O Murillo, J Lora-Tamayo, R Verdaguer, F Tubau, C Cabellos, J Cabo, J Ariza
  [show abstract] [hide abstract]
  ABSTRACT: Efficacy of daptomycin, imipenem or rifampin with fosfomycin was evaluated and compared with daptomycin-rifampin in a tissue-cage model infection caused by MRSA.Strain HUSA 304 was used; MIC/MBC (μg/ml): fosfomycin 4/8, daptomycin 1/4, imipenem 0.25/32 and rifampin 0.03/0.5.Daptomycin-rifampin was confirmed as the most effective therapy against MRSA foreign-body infections. Fosfomycin combinations with high doses of daptomycin and rifampin were efficacious alternative therapies in this setting. Fosfomycin-imipenem was relatively ineffective and did not protect against resistance.
  Antimicrobial Agents and Chemotherapy 10/2012; · 4.84 Impact Factor
• Article: RNAIII inhibiting peptide against foreign-body infection by methicillin-resistant Staphylococcus aureus.

  C Garrigós, O Murillo, J Lora-Tamayo, M Vivas, F Tubau, C Cabellos, J Cabo, J Ariza
  The Journal of infection 10/2012; · 4.13 Impact Factor
• Article: Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.

  C Garrigós, O Murillo, J Lora-Tamayo, R Verdaguer, F Tubau, C Cabellos, J Cabo, J Ariza
  [show abstract] [hide abstract]
  ABSTRACT: Despite the use of daptomycin alone at high doses (greater than 6 mg/kg of body weight/day) against difficult-to-treat infections, clinical failures and resistance appeared. Recently, the combination daptomycin-cloxacillin showed enhanced efficacy in clearing bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA). The aim of this study was to evaluate the efficacy of daptomycin at usual and high doses (equivalent to 6 and 10 mg/kg/day in humans, respectively) in combination with cloxacillin in a rat tissue cage infection model by MRSA and to compare its efficacy to that of daptomycin-rifampin. We used MRSA strain ATCC BAA-39. In the log- and stationary-phase kill curves, daptomycin-cloxacillin improved the bactericidal activity of daptomycin, especially in log phase. For in vivo studies, therapy was administered intraperitoneally for 7 days with daptomycin at 100 mg/kg/day and 45/mg/kg/day (daptomycin 100 and daptomycin 45), daptomycin 100-cloxacillin at 200 mg/kg/12 h, daptomycin 45-cloxacillin, and daptomycin 100-rifampin at 25 mg/kg/12 h. Daptomycin-rifampin was the best therapy (P < 0.05). Daptomycin 45 was the least effective treatment and did not protect against the emergence of resistant strains. There were no differences between the two dosages of daptomycin plus cloxacillin in any situation, and both protected against resistance. The overall effect of the addition of cloxacillin to daptomycin was a significantly greater cure rate (against adhered bacteria) than that for daptomycin alone. In conclusion, daptomycin-cloxacillin enhanced modestly the in vivo efficacy of daptomycin alone against foreign-body infection by MRSA and was less effective than daptomycin plus rifampin. The benefits of adding cloxacillin to daptomycin should be especially evaluated against infections by rifampin-resistant MRSA and for protection against the emergence of daptomycin nonsusceptibility.
  Antimicrobial Agents and Chemotherapy 05/2012; 56(7):3806-11. · 4.84 Impact Factor
• Article: Arthritis related to systemic meningococcal disease: 34 years' experience.

  C Cabellos, J M Nolla, R Verdaguer, I Pelegrin, A Ribera, J Ariza, P F Viladrich
  [show abstract] [hide abstract]
  ABSTRACT: The purpose of this investigation was to assess the clinical characteristics, therapeutic aspects, and outcome of arthritis related to invasive meningococcal disease (IMD). All episodes of bacterial meningitis and IMD are recorded systematically. We selected all episodes of IMD, with or without meningitis, that presented arthritis. From 1977 to 2010, 522 episodes of IMD were treated. Thirty-nine of these (7.5 %, 26 women, mean age 33 years) presented arthritis. Of these 39, 37 (95 %) presented skin lesions and 31 (79 %) had meningitis. Twenty (51 %) had positive blood cultures and six (15 %) had shock. No differences were found in skin lesions, shock, or bacteremia compared to cases without arthritis. In contrast to other septic forms, arthritis related to IMD was cured with short antibiotic therapy and without surgical drainage. There was no mortality. All patients recovered and none presented joint sequelae; however, 13 adult patients (33 %) required long-term treatment with steroids due to persistent symptoms. Arthritis related to IMD most frequently affects the knees and ankles, and may be a cause of fever relapse. Short antibiotic therapy is enough in all cases and surgical drainage is not needed. In some adult patients, especially those over 50 years of age, evolution is torpid and steroid therapy may be required in order to achieve recovery.
  European Journal of Clinical Microbiology 04/2012; 31(10):2661-6. · 2.86 Impact Factor
• Article: Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant Staphylococcus aureus.

  C Garrigós, O Murillo, G Euba, R Verdaguer, F Tubau, C Cabellos, J Cabo, J Ariza
  [show abstract] [hide abstract]
  ABSTRACT: Tigecycline appears as an alternative therapy against methicillin-resistant Staphylococcus aureus (MRSA) with limited clinical experience. We evaluate the efficacy of tigecycline and its combination with rifampin in comparison to that for vancomycin in a rat model of foreign-body infection by MRSA. A tissue-cage infection model were used; therapy with tigecycline, vancomycin, rifampin, tigecycline plus rifampin and vancomycin plus rifampin was administered intraperitoneally for 7 days. The antibiotic efficacy was evaluated in the tissue-cage fluid and in the coverslips (attached bacteria); the emergence of resistance was screened. Among monotherapies rifampin was the best treatment (decrease in log CFU/ml of tissue-cage fluid, 2.75) (P < 0.05). The addition of rifampin improved the efficacy of vancomycin (decrease, 2.28) and tigecycline (decrease, 1.56) in solitary; there were not significantly differences between tigecycline-rifampin (decrease, 3.39) and vancomycin-rifampin (decrease, 3.70), but only the latter was better than rifampin alone (P < 0.05). Resistant strains were only detected using rifampin alone. tigecycline alone was the least effective treatment. Tigecycline-rifampin prevented the emergence of rifampin resistance, thus allowing the benefits of rifampin over time against staphylococcal foreign-body infections, but its efficacy needs to be evaluated in comparison with other anti-MRSA combined therapies.
  The Journal of infection 07/2011; 63(3):229-35. · 4.13 Impact Factor